<DOC>
	<DOCNO>NCT01448824</DOCNO>
	<brief_summary>This 2-part study . Part 1 determine safety tolerability healthy subject increase daily dos LY2484595 14 day achieve blood level LY2484595 much high need therapy . The amount study drug reach bloodstream time take body get rid determine . The effect study drug factor blood relate cholesterol measure . Part 2 determine ketoconazole affect much study drug , LY2484595 , get bloodstream long take get rid . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Study LY2484595 Pharmacokinetics Healthy Subjects</brief_title>
	<detailed_description>This study 2-part , multiple ascend dose ( MAD ) drug drug interaction ( DDI ) study evaluate safety tolerability effect cytochrome P450 ( CYP ) 3A inhibition ketoconazole PK LY2484595 healthy subject . In MAD portion ( Part 1 ) study subject 4 cohort randomize receive either LY2484595 ( dose ascend 100 1800 mg ) placebo . The total duration Part 1 approximately 13 week include screen . Subjects Cohort A participate 2 period 14 day consecutive dosing , follow follow-up visit ≥14-days last dose study drug . Subjects Cohorts B , C , D receive 14 day consecutive dosing follow follow-up visit ≥14 day last dose study drug . Cohorts stagger start ≥7 day previous cohort allow review safety tolerability . The DDI portion study ( Part 2 ) open label consist two period . The total duration Part 2 approximately 10 week . LY2484595 ( 100 mg ) administer Day 1 Period 1 Day 5 Period 2 . In Period 2 , Ketoconazole ( 400 mg ) administer QD total 14 day ( 13 day alone + 1 day LY2484595 ) . There least 14 day washout period Period 1 Period 2 , follow-up great equal 14 day last dose study drug .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination Female subject woman childbearing potential due surgical sterilization ( hysterectomy , bilateral oophorectomy , tubal ligation ) menopause . Postmenopausal define woman age &gt; 45 intact uterus take hormone oral contraceptive within last year , either cessation menses great equal 1 year , 6 12 month spontaneous amenorrhea folliclestimulating hormone ( FSH ) &gt; 40 mIU/mL ( 40 IU/L ) . Have body mass index ( BMI ) 18 32 kg/m^2 , inclusive Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly institutional review board ( IRB ) govern site Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2484595 relate compound , contraindication ketoconazole related compound , allergy component formulation Are person previously complete withdrawn study study investigate LY2484595 , previously receive investigational product Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study , and/or pose difficulty interpretation eventual change occur study Have systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus infection ( HIV ) and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Have use intend use overthecounter prescription medication within 14 day prior dose unless deem acceptable investigator sponsor 's medical monitor Use drug substance know inducer inhibitor CYP3A4 ( eg , St. John 's wort ) , within 30 day prior first dose study drug Have donate blood 500 mL within 30 day prior first dose study drug Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption duration study ( 1 unit equal 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , subject unwilling adhere study caffeine restriction Have daily use great equal 5 tobacco nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) unwilling refrain use tobacco nicotinecontaining product within 7 day prior first dose followup Have consume grapefruit , grapefruit juice , Seville orange , Seville orange juice , Starfruit product contain fruit within 7 day prior first dose study Unwilling refrain daily consumption black licorice contain glycyrrhizic acid ( ie , real licorice ) In opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Low High-density Lipoprotein ( HDL )</keyword>
	<keyword>Cholesterol ( HDL-C )</keyword>
</DOC>